Research Article

Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011

Table 2

Defined daily doses per 1000 inhabitants per day of antiparkinsonian medications prescribed to New Zealand outpatients (1995–2011).

19951996199719981999200020012002200320042005200620072008200920102011Change (%)

Total dopaminergic agents1.761.531.531.481.501.501.501.481.521.521.591.711.821.921.972.052.1119.6
L-dopa total0.780.740.820.840.910.950.980.991.041.051.111.151.191.241.281.341.3876.9
 Madopar0.300.280.300.310.340.350.350.340.340.320.330.330.320.310.310.300.30−0.4
 Sinemet0.480.460.520.520.570.600.630.650.700.720.770.820.870.930.961.011.07121.7
 Sindopa<0.001<0.010.010.010.010.010.010.010.01<0.01<0.010.010.020.029536.4
Amantadine0.040.040.050.060.070.080.090.100.110.120.130.130.150.160.170.170.19350.5
COMTIs total0.020.050.040.040.030.030.030.030.050.070.080.090.100.10326.0
 Tolcapone0.020.050.040.040.030.030.030.030.030.020.020.010.010.02−33.8
 Entacapone<0.010.030.050.060.070.080.093759.6
Dopamine agonist total0.350.290.280.250.230.220.210.200.200.190.190.250.290.310.310.320.33−6.2
 Apomorphine<0.001<0.001<0.01<0.01<0.01<0.01<0.01<0.01<0.01<0.01<0.01<0.01<0.01<0.01<0.01<0.010.0198403.2
 Bromocriptine0.310.250.230.200.180.160.150.130.130.110.100.090.080.060.050.040.04−88.8
 Lisuride0.040.040.030.030.030.030.030.030.030.030.040.040.040.040.030.030.03−30.3
 Pergolide<0.0010.010.010.010.010.020.030.040.040.040.040.030.020.010.010.010.012477.3
 Ropinirole0.010.100.150.190.210.240.253349.8
Selegiline0.590.460.380.310.250.210.180.150.140.130.130.120.120.120.130.120.11−81.7
Anticholinergic total1.401.301.291.231.231.171.080.990.890.810.810.790.770.750.740.730.72−48.6
 Benzotropine1.111.041.040.991.000.950.880.810.710.630.640.630.620.610.600.600.59−46.4
 Orphenadrine0.150.130.130.120.120.110.110.090.090.080.080.070.070.060.060.050.05−64.4
 Procyclidine0.140.130.130.120.110.110.100.090.090.100.090.090.080.080.080.080.07−48.7

COMTIs: catechol-o-methyl transferase inhibitors; L-dopa: levodopa.